Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863

Clinical Pharmacology in Drug Development

Volumn 3, Issue 2, 2014, Pages 109-117

  Johnson, Brendan M ^a   Stier, Brendt A ^a   Caltabiano, Stephen ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

CYP2C8; Food; Gemfibrozil; GSK1278863; Pharmacokinetics

Indexed keywords

GEMFIBROZIL; GSK 1278863; PROLYL HYDROXYLASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FAINTNESS; FEMALE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; STEADY STATE; URINARY TRACT INFECTION; VOMITING;

EID: 84896038260     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.83     Document Type: Article

References (31)

1. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006; 17(1):17-25.
2. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985; 28(1):1-5.
3. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984; 25(2):437-444.
4. Ramanath V, Gupta D, Jain J, Chaudhary K, Nistala R. Anemia and chronic kidney disease: making sense of the recent trials. Rev Recent Clin Trials. 2012; 7(3):187-196.
5. Eckardt KU, Bernhardt WM, Weidemann A, et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int. 2005; 68(Suppl 99):S46-S51.
6. Park JW, Chun YS, Kim MS. Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. J Pharmacol Sci. 2004; 94(3):221-232.
7. Semenza GL, Agani F, Booth G, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int. 1997; 51(2):553-555.
8. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Annu Rev Pathol. 2011; 6:165-192.
9. 2 sensing. Science. 2001; 292(5516):464-468.
10. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998; 95(14):7987-7992.
11. Yu F, White SB, Zhao Q, Lee FS. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA. 2001; 98(17):9630-9635.
12. 2-regulated prolyl hydroxylation. Science. 2001; 292(5516):468-472.
13. Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997; 272(36):22642-22647.
14. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010; 21(12):2151-2156.
15. Muchnik E, Kaplan J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs. 2011; 20(5):645-656.
16. Yan L, Colandrea VJ, Hale JJ. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Pat. 2010; 20(9):1219-1245.
17. Brigandi RA, Johnson B, Oei C, et al. Induction of erythropoiesis in anemic patients by prolyl hydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [Abstract]. J Am Soc Nephrol. 2012; 23:662A.
18. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia. 2003; 46(10):1319-1323.
19. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003; 46(3):347-351.
20. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005; 77(5):404-414.
21. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther. 2010; 88(2):223-230.
22. Steinijans VW, Diletti E. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol. 1983; 24(1):127-136.
23. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1 B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004; 311(1):228-236.
24. Hinton LK, Galetin A, Houston JB. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res. 2008; 25(5):1063-1074.
25. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004; 75(5):455-463.
26. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Toxicol. 1999; 13(6):289-295.
27. Galetin A, Houston JB. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther. 2006; 318(3):1220-1229.
28. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002; 30(6):631-635.
29. Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, Frye RF. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol. 2005; 59(1):70-79.
30. Lageder H, Irsigler K. Evaluation of increasing doses of gemfibrozil in hyperlipoproteinaemia. Proc R Soc Med. 1976; 69(Suppl 2):71-75.
31. Olsson AG, Rossner S, Walldius G, Carlson LA. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia. Proc R Soc Med. 1976; 69(Suppl 2):28-31.